Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Projecting future drug expenditures--2002.

Nilay D Shah1, Lee C Vermeulen, John P Santell

  • 1Center for Drug Policy, University of Wisconsin Hospital and Clinics (UWHC), 100 Highland Avenue, Room F6/133-1530, Madison, WI 53792, USA.

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|February 6, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AACP Argus Commission Forecast 2025.

American journal of pharmaceutical education·2025
Same author

Response to Engle and Colleagues "Commentary on AACP Argus Commission Forecast 2024".

American journal of pharmaceutical education·2025
Same author

Corrigendum to "AACP Argus Commission Forecast 2024" [Am J Pharm Educ 88 (2024) 100763].

American journal of pharmaceutical education·2025
Same author

Guidance for Pharmacy Curricula to Incorporate Health, Wellness, and Health Inequities Stemming From Climate Change: The Report of the 2022-2023 AACP Argus Commission.

American journal of pharmaceutical education·2023
Same author

Catheter-related complications and mortality of atrial fibrillation ablation following introduction of contact force-sensing technology.

BMJ surgery, interventions, & health technologies·2022
Same author

Feasibility of using real-world data in the evaluation of cardiac ablation catheters: a test-case of the National Evaluation System for Health Technology Coordinating Center.

BMJ surgery, interventions, & health technologies·2022

Projected drug costs in 2002 show significant increases, driven by inflation, an aging population, new technologies, and novel pharmaceuticals like drotrecogin alfa for sepsis.

Area of Science:

  • Health Economics
  • Pharmaceutical Policy
  • Healthcare Management

Background:

  • US healthcare expenditures are rising, with pharmaceutical spending increasing faster than overall costs.
  • Key drivers include general inflation, an aging demographic, and the adoption of new medical technologies.

Purpose of the Study:

  • To project drug costs for 2002 and identify key factors influencing these expenditures.
  • To analyze the impact of new pharmaceutical introductions and other market dynamics on healthcare spending.

Main Methods:

  • Analysis of price inflation and non-price factors (volume, therapeutic intensity).
  • Forecasting drug expenditure increases based on historical data and market trends.
  • Review of upcoming pharmaceutical approvals and their potential cost impact.

Related Experiment Videos

Main Results:

  • Forecasted a 15.5% increase in hospital/clinic drug expenditures and 18.5% in ambulatory care for 2002.
  • New drug introductions are a substantial driver of pharmaceutical spending growth.
  • Drotrecogin alfa for sepsis is anticipated to be a high-impact, high-cost agent ($3,000-$10,000/patient).

Conclusions:

  • Technological, demographic, and market changes will significantly influence pharmaceutical expenditures.
  • Understanding these drivers is crucial for effective resource management in healthcare.
  • Legislative actions and generic medications also play a role in medication costs.